T

Tyra Biosciences, Inc. (TYRA)

NMS – Real vaqt narxi. Valyuta: USD

34.87

+0.86 (2.53%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

T

Tyra Biosciences, Inc. (TYRA)

NMS – Real vaqt narxi. Valyuta: USD

34.87

+0.86 (2.53%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: BofA Securities Health Care Conference 2026 Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, May 13, 2026 at 10:40 am PTLocation: Las Vegas, NV TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Format: Fireside chat with Tyler van BurenPresentation Date/Time: Tuesday, May 26, 2026 at 2:00 pm ETLocation: Virtual Jefferies Global Healthcare Conference Format: Hybrid fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, June 3, 2026 at 3:45 pm ETLocation: New York, NY A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

17.04.2026

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.

20.03.2026

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value rose by $10.48 million as a result of the new stake.

02.03.2026

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 - - Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 - CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and highlighted recent corporate progress.

23.02.2026

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU).

19.02.2026

Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: 36th Annual Oppenheimer Life Sciences Healthcare Conference Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Thursday, February 26, 2026 at 12:00pm ETLocation: Virtual 46th Annual TD Cowen Healthcare Conference Format: Hybrid presentation & fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, March 4th, 2026 at 11:50am ETLocation: Boston, MA Leerink Global Healthcare Conference Format: One-on-one investor meetingsDate: March 8-11, 2026Location: Miami, FL 2026 Jefferies Biotech on the Beach Summit Format: One-on-one investor meetingsDate: March 9-11, 2026Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Format: One-on-one investor meetingsDate: March 10-12, 2026Location: Miami, FL A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

23.12.2025

Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally

Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. The director still owns nearly 4 million shares, worth approximately $77.6 million.

Videolar

No Data

There is no data to display

Press-relizlar

17.04.2026

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.

02.03.2026

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 - - Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 - CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and highlighted recent corporate progress.

23.02.2026

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU).

01.12.2025

Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of two key members of its leadership team: Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer.

Search stocks

Tyra Biosciences, Inc. (TYRA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

Tyra Biosciences to Participate in Upcoming Investor Conferences

Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally

Videolar

No Data

Press-relizlar

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer